Latest filing published 02 Mar 2022 for Eagle Pharmaceuticals, INC..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael Shawn Moran: trading record in brief
Michael Shawn Moran, listed as chief executive, appears in our data through filings on Eagle Pharmaceuticals, Inc. shares, published by SEC (Form 4). We count 5 filings; the first trade dates from 5 January 2022 and the latest from 28 February 2022.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The record was last updated on 2 March 2022 with a share grant in Eagle Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Michael Shawn Moran
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,400 shares0Common StockSEC:0001209191-22-015024:0
- 742 shares@ US$45.0326.9% of flowCommon StockSEC:0001209191-22-007222:0
- 210 shares@ US$45.947.8% of flowCommon StockSEC:0001209191-22-006051:0
- 90 shares@ US$50.633.7% of flowCommon StockSEC:0001209191-22-002886:0
- 1,511 shares@ US$50.6961.6% of flowCommon StockSEC:0001209191-22-002419:0
5 of 5 declarations